Deciding whether to pursue additional genetic testing during an IVF cycle can feel overwhelming, especially when the terminology is unfamiliar. One test that comes up often in these conversations is PGT-A testing in IVF. It’s a screening tool that looks at the chromosomes of embryos before one is chosen for transfer, and understanding what it can and cannot tell you is an important part of making an informed decision with your fertility team.
This article explains what PGT-A is, how it fits into the IVF process, what it does and doesn’t detect, and what to consider if you’re exploring this option in Pakistan.
What Is PGT-A Testing?
PGT-A stands for Preimplantation Genetic Testing for Aneuploidy. In simpler terms, it’s a laboratory test performed on embryos created through IVF to check whether they have the expected number of chromosomes.
A few basics help make sense of this:
- Aneuploidy refers to having an abnormal number of chromosomes, either extra or missing copies, rather than the typical 46. Embryos with aneuploidy may not implant, may result in early pregnancy loss, or in some cases may be associated with a chromosomal condition.
- PGT-A was previously known by an older term, PGS (Preimplantation Genetic Screening). The name changed as the field moved toward more precise terminology, but the underlying concept, checking chromosome number before transfer, remains the same.
- Chromosome number matters because embryos need the correct number of chromosomes to develop typically. An abnormal chromosome count is one of several factors that can affect whether an embryo implants and develops into a healthy pregnancy.
It’s important to be clear about what PGT-A is not. This test does not screen for every possible genetic condition. It focuses specifically on chromosome-number abnormalities, not on single-gene disorders or the full range of hereditary conditions. We’ll come back to this distinction later, since it’s one of the most common points of confusion for patients.
How Does PGT-A Work During IVF?
PGT-A is built into a standard IVF cycle rather than requiring a separate procedure. Here’s how it generally fits in:
- Ovarian stimulation: Medications are used to encourage the ovaries to produce multiple eggs in a single cycle.
- Egg retrieval: Once the eggs are mature, they’re retrieved in a minor procedure.
- Fertilization: Eggs are fertilized with sperm in the laboratory, typically using IVF or ICSI techniques.
- Embryo development to the blastocyst stage: Fertilized eggs are cultured for several days until they reach the blastocyst stage, a more advanced stage of embryo development.
- Embryo biopsy: A small number of cells are carefully removed from the outer layer of the blastocyst (the part that will go on to form the placenta, not the fetus itself).
- Genetic analysis: The biopsied cells are sent for laboratory analysis to assess chromosome number.
- Embryo selection and transfer: Your fertility specialist reviews the results alongside other clinical factors and discusses the treatment plan with you, including which embryo(s) may be considered for transfer.
Each of these steps is guided by your fertility specialist, who tailors the process to your individual treatment plan.
What Chromosomal Abnormalities Does PGT-A Screen For?
PGT-A evaluates embryos specifically for chromosome-number abnormalities, also called aneuploidies. Some examples of the conditions this type of screening relates to include:
- Trisomy 21 (Down syndrome)
- Trisomy 18 (Edwards syndrome)
- Trisomy 13 (Patau syndrome)
- Sex chromosome aneuploidies
- Other whole-chromosome gains or losses
It’s worth repeating: PGT-A does not detect all genetic disorders, and it does not guarantee a genetically healthy baby. Many inherited conditions are caused by changes within a single gene rather than by an incorrect chromosome count, and these fall outside what PGT-A is designed to identify. If a family has a known inherited condition they want to screen for, that involves a different type of test entirely, which we’ll cover shortly.
Potential Benefits of PGT-A in IVF
For some patients, PGT-A may offer useful additional information during the IVF process. Potential benefits include:
- It may help identify embryos with chromosome-number abnormalities before transfer.
- It can provide additional information that a fertility specialist may consider, alongside other clinical factors, during embryo selection.
- It may help reduce the likelihood of transferring an embryo that has been identified as aneuploid.
- Depending on individual circumstances, it may be useful in certain IVF situations, such as when there is a specific clinical history that prompts a specialist to recommend it.
These are potential, individualized benefits rather than guarantees. PGT-A does not guarantee IVF success, does not guarantee a healthy baby, does not eliminate the possibility of miscarriage, and does not automatically increase live birth rates for every patient. Whether, and how, PGT-A results should influence a treatment plan is a decision best made with your fertility specialist, based on your specific situation.
Who May Consider PGT-A?
PGT-A isn’t automatically recommended for every IVF patient. A fertility specialist may discuss PGT-A as an option in situations such as:
- Advanced maternal age, since the likelihood of chromosomal abnormalities in embryos can increase with age.
- Recurrent pregnancy loss, where chromosomal factors may be one of several areas a specialist wants to evaluate.
- A previous IVF cycle involving embryos identified with chromosomal abnormalities.
- Certain fertility histories where a specialist believes additional information could be clinically useful.
Because every patient’s situation is different, the decision to pursue PGT-A should be made individually, in consultation with a qualified fertility specialist or genetic counselor who understands your full medical history.
What Are the Limitations of PGT-A?
Understanding the limitations of PGT-A is just as important as understanding its potential benefits.
- PGT-A is a screening test, not a diagnostic guarantee of pregnancy. A favorable result does not guarantee implantation or a successful pregnancy.
- It does not detect every genetic condition. Conditions caused by single-gene mutations or structural chromosome rearrangements fall outside its scope.
- It does not guarantee implantation. Many factors beyond chromosome number affect whether an embryo implants.
- It does not guarantee a healthy pregnancy or baby. Chromosome status is one piece of a much larger picture.
- Embryo biopsy and laboratory testing have inherent limitations, as with any laboratory-based genetic analysis.
- Mosaic or uncertain results can sometimes occur, where an embryo shows a mix of normal and abnormal cells, and interpreting these results requires professional guidance.
Clinical decisions should always be made together with your fertility specialist or a genetic counselor, who can help interpret results in the context of your overall treatment plan.
PGT-A vs PGT-M vs PGT-SR
Patients often come across three related abbreviations, and it helps to see them side by side:
| Test | What It Evaluates |
| PGT-A | Screens embryos for chromosome-number abnormalities (aneuploidy) |
| PGT-M | Targets a specific single-gene (monogenic) disorder already known to run in the family |
| PGT-SR | Evaluates certain structural chromosome rearrangements, such as translocations |
In short: PGT-A looks at whether the chromosome count is correct, PGT-M looks for a specific gene mutation, and PGT-SR looks at chromosome structure rather than number. A fertility specialist or genetic counselor can help determine which of these, if any, is relevant to your circumstances.
PGT-A and Embryo Transfer
When PGT-A is performed, the results become one part of the information your fertility specialist reviews when discussing embryo transfer. Results may be considered alongside embryo morphology (how the embryo looks under the microscope), your medical history, and other clinical factors relevant to your treatment plan.
It’s worth being cautious about how this is often described. PGT-A does not “select the healthiest baby,” and it does not guarantee a particular outcome once an embryo is transferred. It provides information about chromosome number at the embryo stage, nothing more, nothing less, and your fertility specialist is best placed to explain how that information applies to your individual treatment.
PGT-A Testing in Pakistan
For patients in Pakistan exploring PGT-A as part of their IVF journey, ELC Biogen offers the VISTA™ EmbryoSeq PGT-A Test as part of its reproductive health and infertility genetic testing services. This test evaluates embryos for extra or missing chromosomes and is an option that can be discussed for any IVF patient in consultation with their fertility clinic.
ELC Biogen’s reproductive health testing menu also includes carrier screening and chromosome sequencing services, which support different aspects of reproductive and pregnancy-related genetic evaluation.
If you’re considering PGT-A testing in Pakistan, the best next step is to speak with your fertility specialist and reach out to ELC Biogen directly for information on test availability and requirements specific to your situation.
Conclusion
PGT-A testing in IVF can offer additional information about an embryo’s chromosome status before transfer, which some patients and their fertility specialists find useful as part of a broader treatment plan. It is a screening test, not a guarantee; it does not detect every genetic condition, and its relevance depends on each patient’s individual medical history and circumstances.
If you’re exploring PGT-A testing in Pakistan and want to understand how it might fit into your IVF journey, ELC Biogen’s team is available to provide professional information about the VISTA™ EmbryoSeq PGT-A Test and to help guide you toward the right next steps in consultation with your fertility specialist.
Frequently Asked Questions About PGT-A
What is PGT-A testing in IVF?
PGT-A (Preimplantation Genetic Testing for Aneuploidy) is a screening test performed on IVF embryos to check whether they have the expected number of chromosomes before a decision is made about transfer.
When is PGT-A performed?
PGT-A is performed after embryos reach the blastocyst stage during an IVF cycle, using cells obtained through an embryo biopsy.
What does PGT-A detect?
PGT-A detects chromosome-number abnormalities, such as trisomies and sex chromosome aneuploidies. It does not detect single-gene disorders or every possible genetic condition.
Is PGT-A the same as PGT-M?
No. PGT-A screens for chromosome-number abnormalities, while PGT-M targets a specific single-gene disorder that is already known to affect a family.
Does PGT-A guarantee a successful pregnancy?
No. PGT-A is a screening tool that provides additional information; it does not guarantee implantation, pregnancy, or a healthy baby.
Who should consider PGT-A?
PGT-A may be discussed for patients with advanced maternal age, recurrent pregnancy loss, a prior IVF cycle involving chromosomally abnormal embryos, or other specific fertility histories, based on a fertility specialist’s individualized recommendation.
Is PGT-A available in Pakistan?
Yes. ELC Biogen offers the VISTA™ EmbryoSeq PGT-A Test as part of its reproductive health and infertility testing services in Pakistan.
Does PGT-A test for all genetic diseases?
No. PGT-A is limited to chromosome-number abnormalities and does not test for all genetic diseases or guarantee that a resulting pregnancy will be free of genetic conditions.